Literature DB >> 32204707

Peters plus syndrome and Chorioretinal findings associated with B3GLCT gene mutation - a case report.

Ye Elaine Wang1,2, Dhariana Acon Ramirez1, Ta Chen Chang1, Audina Berrocal3.   

Abstract

BACKGROUND: Peters plus syndrome (PPS) is a combination of congenital Peters anomaly and systemic abnormalities. It is inherited most commonly in an autosomal recessive pattern with homozygous B3GLCT mutations. Ocular findings consist predominantly anterior segment abnormalities without posterior segment involvement. CASE
PRESENTATION: In this presentation, we report a case of PPS with homozygous pathogenic variant in B3GLCT who presented with classic anterior segment findings, systemic abnormalities, as well as atypical bilateral chorioretinal atrophy. The chorioretinal findings were characterized with spectral-domain optical coherence tomography.
CONCLUSIONS: Our report expands the phenotypic descriptions of PPS by characterizing posterior segment findings.

Entities:  

Keywords:  Anterior segment dysgenesis; Atrophic chorioretinal lesions; B3GLCT mutation; Peters anomaly; Peters plus syndrome

Mesh:

Substances:

Year:  2020        PMID: 32204707      PMCID: PMC7092513          DOI: 10.1186/s12886-020-01380-6

Source DB:  PubMed          Journal:  BMC Ophthalmol        ISSN: 1471-2415            Impact factor:   2.209


Background

Peters plus syndrome (PPS, also known as Krause-Kivlin or Krause-van Schooneveld-Kivlin syndrome) is characterized by eye abnormalities, characteristic facial features, cleft lip/palate, short limbs with brachydactyly, and developmental delay with intellectual disability [1]. PPS is usually inherited in an autosomal recessive pattern due to biallelic mutations in B3GLCT (also known as B3GALTL), which is associated with an increased risk for miscarriages and stillbirth of affected fetuses [2-4]. Systemic abnormalities may include congenital heart defects, genitourinary anomalies, structural brain malformations, congenital hypothyroidism, and conductive hearing loss [1, 3, 4]. Eye abnormalities in PPS predominantly involve the anterior segment, including corneal clouding, posterior cornea thinning, and iridocorneal adhesions. Based on the anatomic pathology, Peters anomaly may be classified as type I (without keratolenticular adhesion), or type II (with lens abnormalities) [4]. Other ophthalmological defects include iris coloboma and retrolental cyst, although no optical tomographic characterization of chorioretinal findings has been described [1, 5]. In this report, we characterize the chorioretinal findings in a patient with PPS with homozygous pathogenic B3GLCT mutation.

Case presentation

The patient is a 22-month-old Caucasian boy, born at 36 weeks by spontaneous vaginal delivery with normal prenatal care. He had no family history of glaucoma or anterior segment dysgenesis. At birth, he was noted to have bilateral cloudy corneas with no epiphora nor photophobia. He was started on presumptive treatment of topical dorzolamide 2% and hypertonic sodium chloride ophthalmic solution 5% prior to his presentation at the Bascom Palmer Eye Institute. A bedside eye exam revealed a “corneal opacity centrally sparing the periphery” and he was diagnosed with possible congenital glaucoma associated with Peters anomaly. Extraocular findings included short extremities and brachydactyly, cleft palate, characteristic facial features, developmental delay, and pulmonary stenosis (Table 1).
Table 1

Summary of ocular and systemic findings in patients with Peters Anomaly Type 1 and 2, Peters Plus Syndrome, and Our Patient

Peters AnomalyType 1Peters AnomalyType 2Peters Plus SyndromeWith B3GLCT gene mutations aOur Patient
Ocular Findings
 Central corneal clouding++++
 Iris-corneal adhesion++++
 Lens-corneal adhesion++
 Cataractpossiblepossiblepossible+
 Glaucomapossiblepossiblepossiblepossible
 Chorioretinal lesionsrareb+
Systemic Findings
 Short limbs with broad distal extremities++
 Cleft Palate++
 Characteristic facial features++
 Developmental delay/Intellectual disabilities++
 Heart Defectspossible+c
 Genitourinarypossible
 Hearingpossible
 Brain abnormalitiespossible

+Present; − Absent

a All possible mutation including homozygous and compound heterozygous variants. Not necessairly the same point mutation as our patients

bTwo independent reports in literature with no characterization of lesions

c Pulmonary stenosis

Summary of ocular and systemic findings in patients with Peters Anomaly Type 1 and 2, Peters Plus Syndrome, and Our Patient +Present; − Absent a All possible mutation including homozygous and compound heterozygous variants. Not necessairly the same point mutation as our patients bTwo independent reports in literature with no characterization of lesions c Pulmonary stenosis An exam under anesthesia (EUA) was performed the same day. Intraocular pressures (IOP) were 32 mmHg and 27 mmHg in the right eye (OD) and left eye (OS), respectively (Tono-Pen XL, Reichert Inc. Depew, NY). Bright red reflexes were noted prior to dilation in both eyes (OU). Other ocular abnormalities included iridocorneal adhesion superiorly OS and posterior capsular cataract OU. Given the absence of limbal enlargement, normal axial lengths, and an intact red reflex prior to dilation, glaucoma surgery was deferred. Phenylephrine 2.5% OU was added for optical dilation and visual rehabilitation, and topical dorzolamide 2% was continued. Four months later, a second EUA was performed, IOPs were 30 mmHg OD and 35 mmHg OS by Tono-pen. The corneal opacities were noted to have enlarged centrally, though the clear peripheral cornea still maintained intact red reflexes. The irides were noted to have formed whispy attachments to the corneas in both eyes. The view of the lens and posterior structures at this point were suboptimal. A diagnosis of Peters anomaly type 1 was made. Genetic testing subsequently identified a homozygous pathogenic variant in B3GLCT (c. 660 + 1 G > A splice donor; Invitae, Pediatric Genetics Specialty Practice, 60 W Gore St, Orlando, FL 32806, Oct 2017). His axial length measurements and B scan ultrasound estimate of cupping were both stable compared to baseline. Patient was monitored on the same medications without surgical intervention. Genetic screening were offered to patient’s parents but were declined. In the subsequent serial EUA, more adhesions between the iris and cornea OS were noted despite the generally improved corneal opacities OU. Posterior segment improved as the media opacity cleared. Fluorescein angiography (FA) was performed (RetCam3, Ophthalmic Imaging System, Natus Medical), and spectral-domain optical coherence tomography (SD-OCT) images were obtain (Spectralis flex module, Heidelberg Engineering). The optic discs were noted to have morning glory-like appearances suggestive of colobomatous changes, with a cup to disc ratio of approximately 0.7 OU. Diffuse chorioretinal atrophies were noted [Fig. 1a-b]. The right eye had a well-defined white-yellowish, comet shaped lesion along the superotemporal arcade [Fig. 1 a]. A similar lesion that was well-circumscribed, oval-shaped and atrophic was seen in the central macula of the left eye [Fig. 1 b]. FA demonstrated early hyperfluorescence of the lesion with no leakage in the right eye, and early hyperfluorescence secondary to a window defect corresponding to the macular lesion in the left eye. Late frames of the FA showed hyperfluorescence of the atrophic lesions [Fig. 1 c-d]. There were neither leakage from the optic disc, nor vascular abnormalities in the peripheral retina. Intraoperative SD-OCT of the macula showed severe diffuse thinning of the retina and choroid in the atrophic lesions. Additionally, in the left eye oval shaped atrophic lesion, a complete loss of retinal structure was noted [Fig. 1E-F]. Written informed consent to publish the acquired images were obtained from the patient’s guardians.
Fig. 1

a (right eye) and b (left eye) show the color fundus photos, areas of demarcated severe chorioretinal atrophy can be seen (yellow arrows). c (right eye) and d(left eye) show late phases of fluorescein angiography with hyperfluorescence of the atrophic lesions (red arrows) 1E (right eye) and f (left eye) show scan of spectrum domain optic coherence tomography trough the areas of atrophy, generalized thinning of all retina layers and choroid are demonstrated (white asterisks)

a (right eye) and b (left eye) show the color fundus photos, areas of demarcated severe chorioretinal atrophy can be seen (yellow arrows). c (right eye) and d(left eye) show late phases of fluorescein angiography with hyperfluorescence of the atrophic lesions (red arrows) 1E (right eye) and f (left eye) show scan of spectrum domain optic coherence tomography trough the areas of atrophy, generalized thinning of all retina layers and choroid are demonstrated (white asterisks)

Discussion and conclusion

In this case report, we used multimodal imaging to characterize the bilateral chorioretinal lesions in a young patient with PPS associated with a homozygous B3GLCT mutation. Both eyes had diffuse chorioretinal atrophy, with very well-defined areas of thinning/absence of the retina layers located in the posterior pole. Reis et al. described a retinal coloboma-like lesion in a premature PPS patient with B3GLCT mutation [6]. However, the lesion was not further characterized in their report [6]. Weh and colleagues reported one patient with chorioretinal changes in their cohort of 9 PPS patients with B3GLCT mutations, but a detailed description of the lesion was similarly not presented [7]. The B3GLCT gene (chromosome 13) was identified by Heinonen et al. and encodes a glucosyltransferase protein which catalyzes glycosylation of other proteins [8]. This protein mediates the non-canonical endoplasmic reticulum quality-control mechanism, which involves identifying and stabilizing properly folded proteins through glycosylation [9]. As of 2019, all 15 B3GLCT mutations reported in the literature (including c.660 + 1G > A, the most common allele) were predicted to cause truncated protein products that result in complete loss of function [6, 10]. The B3GLCT gene transcripts have been found in various human tissues including the heart, kidney, and brain [8, 11]. A loss of function mutation in B3GLCT gene likely causes malfunctioning in protein glycosylation resulting in anomalies of multiple organ systems [8, 11]. The mechanism resulting in the chorioretinal findings remain uncertain. There are several limitations to our case report. It is possible that the chorioretinal findings were either isolated events independent of the genetic mutation or were associated with other genetic defects that were not identified. The timing of the development of such chorioretinal changes was unclear in our patient. His corneal opacity initially precluded adequate examination of his posterior pole, potentially delaying the identification of the retinal abnormalities. Alternatively, the chorioretinal findings could be an acquired, progressive process rather than a congenital one. Despite these limitations, we believe our findings contribute to the phenotypic characterization of B3GLCT mutation and PPS.
  11 in total

1.  Peters' anomaly. The spectrum of associated ocular and systemic malformations.

Authors:  E Heon; M Barsoum-Homsy; L Cevrette; J L Jacob; J Milot; R Polemeno; M A Musarella
Journal:  Ophthalmic Paediatr Genet       Date:  1992-06

2.  Novel B3GALTL mutations in classic Peters plus syndrome and lack of mutations in a large cohort of patients with similar phenotypes.

Authors:  E Weh; L M Reis; R C Tyler; D Bick; W J Rhead; S Wallace; T L McGregor; S K Dills; M-C Chao; J C Murray; E V Semina
Journal:  Clin Genet       Date:  2013-09-17       Impact factor: 4.438

3.  Mutation analysis of B3GALTL in Peters Plus syndrome.

Authors:  Linda M Reis; Rebecca C Tyler; Omar Abdul-Rahman; Pamela Trapane; Robert Wallerstein; Diane Broome; Jodi Hoffman; Aneal Khan; Christina Paradiso; Nitin Ron; Amanda Bergner; Elena V Semina
Journal:  Am J Med Genet A       Date:  2008-10-15       Impact factor: 2.802

4.  Peters'-plus: a new syndrome.

Authors:  M J van Schooneveld; J W Delleman; F A Beemer; E M Bleeker-Wagemakers
Journal:  Ophthalmic Paediatr Genet       Date:  1984-12

5.  Murine ortholog of the novel glycosyltransferase, B3GTL: primary structure, characterization of the gene and transcripts, and expression in tissues.

Authors:  Taisto Y K Heinonen; Markku Pelto-Huikko; Leena Pasternack; Markku Mäki; Heikki Kainulainen
Journal:  DNA Cell Biol       Date:  2006-08       Impact factor: 3.311

6.  Peters Plus syndrome is caused by mutations in B3GALTL, a putative glycosyltransferase.

Authors:  Saskia A J Lesnik Oberstein; Marjolein Kriek; Stefan J White; Margot E Kalf; Karoly Szuhai; Johan T den Dunnen; Martijn H Breuning; Raoul C M Hennekam
Journal:  Am J Hum Genet       Date:  2006-07-19       Impact factor: 11.025

7.  Peters plus syndrome mutations disrupt a noncanonical ER quality-control mechanism.

Authors:  Deepika Vasudevan; Hideyuki Takeuchi; Sumreet Singh Johar; Elaine Majerus; Robert S Haltiwanger
Journal:  Curr Biol       Date:  2014-12-24       Impact factor: 10.834

Review 8.  The Peters' plus syndrome: a review.

Authors:  Liesbeth J J M Maillette de Buy Wenniger-Prick; Raoul C M Hennekam
Journal:  Ann Genet       Date:  2002 Apr-Jun

9.  Peters Plus syndrome is a new congenital disorder of glycosylation and involves defective Omicron-glycosylation of thrombospondin type 1 repeats.

Authors:  Daniel Hess; Jeremy J Keusch; Saskia A Lesnik Oberstein; Raoul C M Hennekam; Jan Hofsteenge
Journal:  J Biol Chem       Date:  2008-01-16       Impact factor: 5.157

Review 10.  Peters'-plus syndrome is a congenital disorder of glycosylation caused by a defect in the beta1,3-glucosyltransferase that modifies thrombospondin type 1 repeats.

Authors:  Taisto Y K Heinonen; Markku Maki
Journal:  Ann Med       Date:  2009       Impact factor: 4.709

View more
  1 in total

1.  A mutation in DOP1B identified as a probable cause for autosomal recessive Peters anomaly in a consanguineous family.

Authors:  Ensieh Darbari; Davood Zare-Abdollahi; Afagh Alavi; Mozhgan Rezaei Kanavi; Sepehr Feizi; Seyed Bagher Hosseini; Alireza Baradaran-Rafii; Hamid Ahmadieh; Shohreh Issazadeh-Navikas; Elahe Elahi
Journal:  Mol Vis       Date:  2020-11-25       Impact factor: 2.367

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.